Novartis Hit With Subpoena From DOJ Over Marketing and Pricing of Heart Drug Entresto

By PacConAdmin | October 28, 2021

Novartis has received a request from the Department of Justice (DOJ) asking for information about the marketing and pricing of Entresto, the company’s blockbuster combination sacubitril/valsartan drug for heart failure.
Source: Drug Industry Daily

Posted in Drug Industry Daily